The Institute for Clinical and Economic Review reports that out of 10 drugs with substantial price increases in 2020, seven lacked new clinical evidence. After drug rebates and concessions, the net price increases on these seven drugs cost $1.67 billion in annual drug spending, and $1.4 billion of that was due to Humira. ICER chose 10 drugs from 250 drugs with the highest net sales in 2020 and reviewed evidence submitted by drug makers to determine whether price increases were...